The use of therapeutic plasma exchange as adjunctive therapy in the treatment of coronavirus disease 2019: A critical appraisal of the current evidence

Wen Lu, Walter Kelley, Deanna C. Fang, Sarita Joshi, Young Kim, Monika Paroder, Yvette Tanhehco, Minh Ha Tran, Huy P. Pham

Research output: Contribution to journalReview articlepeer-review

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a major pandemic. While vaccine development moves forward, optimal treatment continues to be explored. Efforts include an ever-expanding number of clinical trials along with newly proposed experimental and off-label investigational therapies; one of which is therapeutic plasma exchange (TPE). There have been a number of publications on TPE use as adjunctive therapy for coronavirus disease 2019 (COVID-19), but no prospective randomized controlled trials (RCTs) have been completed. This article critically appraises the current available evidence on TPE as a treatment modality for SARS-CoV-2 infection.

Original languageEnglish (US)
JournalJournal of Clinical Apheresis
DOIs
StateAccepted/In press - 2021

Keywords

  • COVID-19
  • SARS-CoV-2
  • plasma exchange

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The use of therapeutic plasma exchange as adjunctive therapy in the treatment of coronavirus disease 2019: A critical appraisal of the current evidence'. Together they form a unique fingerprint.

Cite this